Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3023MR)

This product GTTS-WQ3023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3023MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11170MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ502MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ5214MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ13409MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ1362MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ6275MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ12873MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ8984MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ILV-094
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW